Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice

Nucleot(s)ide analogues and peginterferon (PEG-IFN) treatment are the only approved therapies for chronic hepatitis B virus (HBV) infection. However, complete eradication of the virus, as indicated by persistent loss of hepatitis B surface antigen (HBsAg), is rare among treated patients. This is due...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Uchida, Takuro, Imamura, Michio, Hayes, C. Nelson, Hiraga, Nobuhiko, Kan, Hiromi, Tsuge, Masataka, Abe-Chayama, Hiromi, Zhang, Yizhou, Makokha, Grace Naswa, Aikata, Hiroshi, Miki, Daiki, Ochi, Hidenori, Ishida, Yuji, Tateno, Chise, Chayama, Kazuaki
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2017
Matèries:
Antiviral Agents
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5571312/
https://ncbi.nlm.nih.gov/pubmed/28696237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00725-17
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars